Cargando…
The Evolution of BRAF Activation in Non-Small-Cell Lung Cancer
Non-small-cell lung cancer (NSCLC) is the most common subtype of lung cancer, of which approximate 4% had BRAF activation, with an option for targeted therapy. BRAF activation comprises of V600 and non-V600 mutations, fusion, rearrangement, in-frame deletions, insertions, and co-mutations. In additi...
Autores principales: | Zhang, Longyao, Zheng, Linpeng, Yang, Qiao, Sun, Jianguo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9326470/ https://www.ncbi.nlm.nih.gov/pubmed/35912223 http://dx.doi.org/10.3389/fonc.2022.882940 |
Ejemplares similares
-
BRAF-Mutated Non-Small Cell Lung Cancer: Current Treatment Status and Future Perspective
por: Yan, Ningning, et al.
Publicado: (2022) -
Therapeutic strategies for BRAF mutation in non-small cell lung cancer: a review
por: Puri, Megha, et al.
Publicado: (2023) -
Clinical Characteristics and Treatment Outcomes of 65 Patients With BRAF-Mutated Non-small Cell Lung Cancer
por: Mu, Yuxin, et al.
Publicado: (2020) -
Clinical associations and prognostic value of site-specific metastases in non-small cell lung cancer: A population-based study
por: Xu, Zihan, et al.
Publicado: (2019) -
Immune Response on Optimal Timing and Fractionation Dose for Hypofractionated Radiotherapy in Non–Small-Cell Lung Cancer
por: Zhao, Xianlan, et al.
Publicado: (2022)